Ongoing treatment(s)-Radiation Posts on Medivizor

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Posted by Medivizor on Sep 27, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of radiation therapy (RT) dose escalation and the addition of short-term (ST) or long-term (LT) androgen deprivation therapy (ADT) to RT in men with localized prostate cancer (PCa). The data showed that the addition of ST or LT-ADT to RT improved survival without metastasis in these patients,...

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Posted by Medivizor on Mar 20, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk factors associated with acute radiation dermatitis (ARD; skin irritation) after radiotherapy (RT) in patients with breast cancer (BC). The data showed that patients with diabetes, smokers, and those with a body mass index (BMI; a measure of body weight in relation to height) of more than 25 kg/m2 had a...

Evaluating the safety and effectiveness of nimotuzumab combined with chemoradiotherapy for patients with squamous cell lung cancer.

Posted by Medivizor on Aug 22, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of nimotuzumab (Theraloc) combined with chemoradiotherapy (CRT) for the treatment of patients with locally advanced squamous non-small cell lung cancer (SqNSCLC). The data showed that nimotuzumab plus CRT had similar survival outcomes compared to CRT alone, but with a lower...

Evaluating the effectiveness and safety a second radiation therapy in patients with prostate cancer.

Posted by Medivizor on May 16, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of re-irradiation in the treatment of patients with relapsed prostate cancer (PCa). The data showed that the use of re-irradiation in these patients was associated with good outcomes and low toxicity. Some background Radiotherapy (RT) is an effective treatment for localized prostate...

Evaluating the effectiveness and optimal duration of additional androgen deprivation therapy after radiotherapy in locally advanced prostate cancer

Posted by Medivizor on Apr 25, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes and effectiveness of administering additional (adjuvant) androgen deprivation therapy (A-ADT) for long-term after radiotherapy (RT) in high-risk or very high-risk locally advanced prostate cancer (LAPC). The study found that the addition of A-ADT longer than 1 year after RT showed good treatment outcomes...

How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?

Posted by Medivizor on Feb 26, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the timing between chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer (LARC). The study found that patients who had surgery more than 10 weeks after CRT had the best outcome. Some background Rectal cancer is commonly treated with surgery to remove the tumor. LARC is...

Evaluating the effects of radiation doses on erectile function in localized prostate cancer treated with permanent prostate brachytherapy.

Posted by Medivizor on Jan 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the relationship between radiation doses in prostate brachytherapy (BT) and erectile function reduction in patients with localized prostate cancer (PCa). The data showed that sexual function decreased over time with higher doses of BT. Some background Localized prostate cancer (PCa) is a form of cancer that...

Should patients with prostate cancer get androgen deprivation therapy before or after radiotherapy?

Posted by Medivizor on Dec 20, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of giving androgen deprivation therapy (ADT) before or after radiotherapy (RT) for prostate cancer (PCa). The study found that treatment with RT followed by ADT increased patient survival without the spread of the disease. Some background PCa can often spread to other locations within the...

Looking for patients with stage III non-small cell lung cancer to trial a treatment combination with radiotherapy

Posted by Medivizor on Aug 23, 2020 in Lung cancer | 0 comments

In a nutshell This study is looking to examine the effectiveness of durvalumab (Imfinzi) and consolidation stereotactic body radiation therapy (SBRT) after chemoradiation for locally advanced stage III non-small-cell lung cancer (NSCLC). The main outcomes to be measured are the occurrence of side effects and the survival without cancer...

Does anti-clotting medication improve treatment results for patients with prostate cancer?

Posted by Medivizor on Jun 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined if lower numbers of platelets (blood cells involved in forming clots) and anti-clotting medications were associated with treatment results in patients with prostate cancer (PC). The authors found that lower numbers of platelets and anti-clotting medication were associated with higher treatment...

Can bowel side effects caused by radiotherapy be reduced by a spacer tool in patients with prostate cancer?

Posted by Medivizor on May 30, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined if a hydrogel spacer tool improved long-term quality of life for patients with prostate cancer (PC) who received radiotherapy (RT). The results showed that the spacer significantly reduced bowel side effects and improved patients’ quality of life. Some background RT is an effective therapy for patients with...

How long should hormonal treatment be given to patients with locally advanced prostate cancer?

Posted by Medivizor on Apr 14, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared 6-month and 18-month courses of hormonal anti-androgen treatment and radiotherapy (RT) in patients with locally advanced prostate cancer (LAPC). The results showed that 18-month treatment was most effective, especially when used with high dose brachytherapy RT. Some background Androgens (such as testosterone) are...

Ongoing treatment(s)-Radiation Posts on Medivizor

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Evaluating the safety and effectiveness of nimotuzumab combined with chemoradiotherapy for patients with squamous cell lung cancer.

Evaluating the effectiveness and safety a second radiation therapy in patients with prostate cancer.

Evaluating the effectiveness and optimal duration of additional androgen deprivation therapy after radiotherapy in locally advanced prostate cancer

How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?

Evaluating the effects of radiation doses on erectile function in localized prostate cancer treated with permanent prostate brachytherapy.

Should patients with prostate cancer get androgen deprivation therapy before or after radiotherapy?

Looking for patients with stage III non-small cell lung cancer to trial a treatment combination with radiotherapy

Does anti-clotting medication improve treatment results for patients with prostate cancer?

Can bowel side effects caused by radiotherapy be reduced by a spacer tool in patients with prostate cancer?

How long should hormonal treatment be given to patients with locally advanced prostate cancer?

Categories

Recent Posts

Archives

Ongoing treatment(s)-Radiation Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email